Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade A 2.9 -1.69% -0.05
AGEN closed down 1.69 percent on Monday, May 20, 2019, on 89 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical AGEN trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Overbought Stochastic Strength 0.00%
Spinning Top Other -1.69%
Calm After Storm Range Contraction -1.69%
Overbought Stochastic Strength -1.69%
Calm After Storm Range Contraction -1.69%
NR7 Range Contraction -1.69%
Overbought Stochastic Strength -1.69%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.36%
Calm After Storm Range Contraction -2.36%

Older signals for AGEN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Medicine Biotechnology Health Cancer Clinical Medicine Infectious Diseases Cancers Alzheimer's Disease Non Small Cell Lung Cancer Vaccination Melanoma Vaccine Metastatic Melanoma Renal Cell Carcinoma Glioma Malaria Cancer Vaccines Oncophage Shingles Experimental Cancer Treatments Genital Herpes Herpes Simplex Research
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.88
52 Week Low 1.54
Average Volume 1,001,544
200-Day Moving Average 2.5134
50-Day Moving Average 2.7952
20-Day Moving Average 2.749
10-Day Moving Average 2.871
Average True Range 0.1329
ADX 19.07
+DI 17.6088
-DI 17.4098
Chandelier Exit (Long, 3 ATRs ) 2.6013
Chandelier Exit (Short, 3 ATRs ) 2.8687
Upper Bollinger Band 3.0526
Lower Bollinger Band 2.4454
Percent B (%b) 0.75
BandWidth 22.088032
MACD Line 0.0536
MACD Signal Line 0.0192
MACD Histogram 0.0344
Fundamentals Value
Market Cap 289.16 Million
Num Shares 99.7 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -2.30
Price-to-Sales 8.62
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.11
Resistance 3 (R3) 3.11 3.05 3.08
Resistance 2 (R2) 3.05 2.99 3.05 3.06
Resistance 1 (R1) 2.97 2.96 2.94 2.97 3.05
Pivot Point 2.91 2.91 2.89 2.91 2.91
Support 1 (S1) 2.83 2.85 2.80 2.83 2.75
Support 2 (S2) 2.77 2.82 2.77 2.74
Support 3 (S3) 2.69 2.77 2.73
Support 4 (S4) 2.69